{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38177135", "DateCompleted": {"Year": "2024", "Month": "01", "Day": "11"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "11"}, "Article": {"Language": ["eng"], "ELocationID": ["11", "10.1038/s41392-023-01706-y"], "ArticleDate": [{"Year": "2024", "Month": "01", "Day": "05"}], "Journal": {"ISSN": "2059-3635", "JournalIssue": {"Volume": "9", "Issue": "1", "PubDate": {"Year": "2024", "Month": "Jan", "Day": "05"}}, "Title": "Signal transduction and targeted therapy", "ISOAbbreviation": "Signal Transduct Target Ther"}, "ArticleTitle": "Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.", "Pagination": {"StartPage": "11", "MedlinePgn": "11"}, "Abstract": {"AbstractText": ["Non-small cell lung cancer (NSCLC) ranks as one of the leading causes of cancer-related deaths worldwide. Despite the prominence and effectiveness of kinase-target therapies in NSCLC treatment, these drugs are suitable for and beneficial to a mere ~30% of NSCLC patients. Consequently, the need for novel strategies addressing NSCLC remains pressing. Deubiquitinases (DUBs), a group of diverse enzymes with well-defined catalytic sites that are frequently overactivated in cancers and associated with tumorigenesis and regarded as promising therapeutic targets. Nevertheless, the mechanisms by which DUBs promote NSCLC remain poorly understood. Through a global analysis of the 97 DUBs' contribution to NSCLC survival possibilities using The Cancer Genome Atlas (TCGA) database, we found that high expression of Josephin Domain-containing protein 2 (JOSD2) predicted the poor prognosis of patients. Depletion of JOSD2 significantly impeded NSCLC growth in both cell/patient-derived xenografts in vivo. Mechanically, we found that JOSD2 restricts the kinase activity of LKB1, an important tumor suppressor generally inactivated in NSCLC, by removing K6-linked polyubiquitination, an action vital for maintaining the integrity of the LKB1-STRAD-MO25 complex. Notably, we identified the first small-molecule inhibitor of JOSD2, and observed that its pharmacological inhibition significantly arrested NSCLC proliferation in vitro/in vivo. Our findings highlight the vital role of JOSD2 in hindering LKB1 activity, underscoring the therapeutic potential of targeting JOSD2 in NSCLC, especially in those with inactivated LKB1, and presenting its inhibitors as a promising strategy for NSCLC treatment."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Yuan", "ForeName": "Tao", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 311199, China."}], "LastName": "Zeng", "ForeName": "Chenming", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ministry of Education Key Laboratory of Chinese Medicinal Plants Resource from Lingnan, Research Center of Medicinal Plants Resource Science and Engineering, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China."}], "LastName": "Liu", "ForeName": "Jiawei", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Zhao", "ForeName": "Chenxi", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Ge", "ForeName": "Fujing", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Li", "ForeName": "Yuekang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Qian", "ForeName": "Meijia", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Du", "ForeName": "Jiamin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Wang", "ForeName": "Weihua", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Li", "ForeName": "Yonghao", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Liu", "ForeName": "Yue", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Drug Safety Evaluation and Research of Zhejiang University, Hangzhou, 310058, China."}], "LastName": "Dai", "ForeName": "Xiaoyang", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310006, China."}], "LastName": "Zhou", "ForeName": "Jianya", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, 310002, China."}], "LastName": "Chen", "ForeName": "Xueqin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, 310002, China."}], "LastName": "Ma", "ForeName": "Shenglin", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. hongzhu@zju.edu.cn."}, {"Identifier": [], "Affiliation": "Cancer Center of Zhejiang University, Hangzhou, China. hongzhu@zju.edu.cn."}], "LastName": "Zhu", "ForeName": "Hong", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. qiaojunhe@zju.edu.cn."}, {"Identifier": [], "Affiliation": "Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, Hangzhou, China. qiaojunhe@zju.edu.cn."}], "LastName": "He", "ForeName": "Qiaojun", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. yang924@zju.edu.cn."}], "LastName": "Yang", "ForeName": "Bo", "Initials": "B"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Signal Transduct Target Ther", "NlmUniqueID": "101676423", "ISSNLinking": "2059-3635"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Protein Serine-Threonine Kinases"}, {"RegistryNumber": "EC 3.4.19.12", "NameOfSubstance": "JOSD2 protein, human"}, {"RegistryNumber": "EC 3.4.19.12", "NameOfSubstance": "Deubiquitinating Enzymes"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "STK11 protein, human"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "genetics", "pathology"], "DescriptorName": "Carcinoma, Non-Small-Cell Lung"}, {"QualifierName": [], "DescriptorName": "Genes, Tumor Suppressor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Liver"}, {"QualifierName": ["drug therapy", "genetics", "pathology"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Protein Serine-Threonine Kinases"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Deubiquitinating Enzymes"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u2013454. doi: 10.1038/nature25183.", "ArticleIdList": ["10.1038/nature25183", "29364287"]}, {"Citation": "Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N. Engl. J. Med. 2017;377:849\u2013861. doi: 10.1056/NEJMra1703413.", "ArticleIdList": ["10.1056/NEJMra1703413", "28854088"]}, {"Citation": "Hirsch FR, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311. doi: 10.1016/S0140-6736(16)30958-8.", "ArticleIdList": ["10.1016/S0140-6736(16)30958-8", "27574741"]}, {"Citation": "Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 2018;17:57\u201378. doi: 10.1038/nrd.2017.152.", "ArticleIdList": ["10.1038/nrd.2017.152", "PMC7097658", "28959952"]}, {"Citation": "Luise C, et al. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS ONE. 2011;6:e15891. doi: 10.1371/journal.pone.0015891.", "ArticleIdList": ["10.1371/journal.pone.0015891", "PMC3026797", "21283576"]}, {"Citation": "Fraile JM, et al. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31:2373\u20132388. doi: 10.1038/onc.2011.443.", "ArticleIdList": ["10.1038/onc.2011.443", "21996736"]}, {"Citation": "Zhang B, et al. PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis. Cell Rep. 2017;19:2289\u20132303. doi: 10.1016/j.celrep.2017.05.067.", "ArticleIdList": ["10.1016/j.celrep.2017.05.067", "28614715"]}, {"Citation": "Krassikova L, et al. The deubiquitinase JOSD2 is a positive regulator of glucose metabolism. Cell Death Differ. 2021;28:1091\u20131109. doi: 10.1038/s41418-020-00639-1.", "ArticleIdList": ["10.1038/s41418-020-00639-1", "PMC7937685", "33082514"]}, {"Citation": "Boudeau J, et al. Analysis of the LKB1-STRAD-MO25 complex. J. Cell Sci. 2004;117:6365\u20136375. doi: 10.1242/jcs.01571.", "ArticleIdList": ["10.1242/jcs.01571", "15561763"]}, {"Citation": "Hawley SA, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003;2:28\u201343. doi: 10.1186/1475-4924-2-28.", "ArticleIdList": ["10.1186/1475-4924-2-28", "PMC333410", "14511394"]}, {"Citation": "Baas AF, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 2003;22:3062\u20133072. doi: 10.1093/emboj/cdg292.", "ArticleIdList": ["10.1093/emboj/cdg292", "PMC162144", "12805220"]}, {"Citation": "Zeqiraj E, et al. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science. 2009;326:1707\u20131711. doi: 10.1126/science.1178377.", "ArticleIdList": ["10.1126/science.1178377", "PMC3518268", "19892943"]}, {"Citation": "Carretero J, et al. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene. 2004;23:4037\u20134040. doi: 10.1038/sj.onc.1207502.", "ArticleIdList": ["10.1038/sj.onc.1207502", "15021901"]}, {"Citation": "Carretero J, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010;17:547\u2013559. doi: 10.1016/j.ccr.2010.04.026.", "ArticleIdList": ["10.1016/j.ccr.2010.04.026", "PMC2901842", "20541700"]}, {"Citation": "Matsumoto S, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007;26:5911\u20135918. doi: 10.1038/sj.onc.1210418.", "ArticleIdList": ["10.1038/sj.onc.1210418", "PMC3457639", "17384680"]}, {"Citation": "Zheng B, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell. 2009;33:237\u2013247. doi: 10.1016/j.molcel.2008.12.026.", "ArticleIdList": ["10.1016/j.molcel.2008.12.026", "PMC2715556", "19187764"]}, {"Citation": "Esteller M, et al. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene. 2000;19:164\u2013168. doi: 10.1038/sj.onc.1203227.", "ArticleIdList": ["10.1038/sj.onc.1203227", "10644993"]}, {"Citation": "Lee SW, et al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol. Cell. 2015;57:1022\u20131033. doi: 10.1016/j.molcel.2015.01.015.", "ArticleIdList": ["10.1016/j.molcel.2015.01.015", "PMC5337120", "25728766"]}, {"Citation": "Aguirre-Gamboa R, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE. 2013;8:e74250. doi: 10.1371/journal.pone.0074250.", "ArticleIdList": ["10.1371/journal.pone.0074250", "PMC3774754", "24066126"]}, {"Citation": "Wang T, et al. Accuracy of using a patient-derived tumor organoid culture model to predict the response to chemotherapy regimens in stage IV colorectal cancer: a blinded study. Dis. Colon Rectum. 2021;64:833\u2013850. doi: 10.1097/DCR.0000000000001971.", "ArticleIdList": ["10.1097/DCR.0000000000001971", "33709991"]}, {"Citation": "Shaw RJ, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91\u201399. doi: 10.1016/j.ccr.2004.06.007.", "ArticleIdList": ["10.1016/j.ccr.2004.06.007", "15261145"]}, {"Citation": "Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene. 2008;27:6908\u20136919. doi: 10.1038/onc.2008.342.", "ArticleIdList": ["10.1038/onc.2008.342", "19029933"]}, {"Citation": "Seki T, et al. JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis. J. Biol. Chem. 2013;288:17145\u201317155. doi: 10.1074/jbc.M113.463406.", "ArticleIdList": ["10.1074/jbc.M113.463406", "PMC3682520", "23625928"]}, {"Citation": "Grasty KC, Weeks SD, Loll PJ. Structural insights into the activity and regulation of human Josephin-2. J. Struct. Biol. X. 2019;3:100011\u2013100019.", "ArticleIdList": ["PMC7337049", "32647816"]}, {"Citation": "Hanpude P, Bhattacharya S, Dey AK, Maiti TK. Deubiquitinating enzymes in cellular signaling and disease regulation. IUBMB Life. 2015;67:544\u2013555. doi: 10.1002/iub.1402.", "ArticleIdList": ["10.1002/iub.1402", "26178252"]}, {"Citation": "Atanassov BS, et al. ATXN7L3 and ENY2 coordinate activity of multiple H2B deubiquitinases important for cellular proliferation and tumor growth. Mol. Cell. 2016;62:558\u2013571. doi: 10.1016/j.molcel.2016.03.030.", "ArticleIdList": ["10.1016/j.molcel.2016.03.030", "PMC4874879", "27132940"]}, {"Citation": "Deng M, et al. Deubiquitination and activation of AMPK by USP10. Mol. Cell. 2016;61:614\u2013624. doi: 10.1016/j.molcel.2016.01.010.", "ArticleIdList": ["10.1016/j.molcel.2016.01.010", "PMC4836875", "26876938"]}, {"Citation": "Huang X, et al. Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol. Cell. 2011;42:511\u2013523. doi: 10.1016/j.molcel.2011.03.027.", "ArticleIdList": ["10.1016/j.molcel.2011.03.027", "21596315"]}, {"Citation": "Altun M, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 2011;18:1401\u20131412. doi: 10.1016/j.chembiol.2011.08.018.", "ArticleIdList": ["10.1016/j.chembiol.2011.08.018", "22118674"]}, {"Citation": "Liu, J. et al. The invention discloses a naphthoquinone triazole core skeleton derivative compound, a preparation method and application thereof. China patent CN110218198A (2019)."}, {"Citation": "Martinez Molina D, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84\u201387. doi: 10.1126/science.1233606.", "ArticleIdList": ["10.1126/science.1233606", "23828940"]}, {"Citation": "Sacco JJ, et al. The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene. 2014;33:4265\u20134272. doi: 10.1038/onc.2013.512.", "ArticleIdList": ["10.1038/onc.2013.512", "PMC4351423", "24292675"]}, {"Citation": "Shi Z, et al. Ataxin-3 promotes testicular cancer cell proliferation by inhibiting anti-oncogene PTEN. Biochem Biophys. Res. Commun. 2018;503:391\u2013396. doi: 10.1016/j.bbrc.2018.06.047.", "ArticleIdList": ["10.1016/j.bbrc.2018.06.047", "29902454"]}, {"Citation": "Buus R, et al. Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells. Curr. Biol. 2009;19:1463\u20131466. doi: 10.1016/j.cub.2009.07.040.", "ArticleIdList": ["10.1016/j.cub.2009.07.040", "PMC2764384", "19699092"]}, {"Citation": "Wu X, et al. JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. Cell Death Differ. 2020;27:55\u201370. doi: 10.1038/s41418-019-0339-0.", "ArticleIdList": ["10.1038/s41418-019-0339-0", "PMC7206032", "31043700"]}, {"Citation": "Qian M, et al. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression. Acta Pharm. Sin. B. 2021;11:4008\u20134019. doi: 10.1016/j.apsb.2021.04.003.", "ArticleIdList": ["10.1016/j.apsb.2021.04.003", "PMC8727894", "35024322"]}, {"Citation": "Huang Y, et al. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation. Cell Biol. Int. 2022;46:1089\u20131097. doi: 10.1002/cbin.11812.", "ArticleIdList": ["10.1002/cbin.11812", "35568970"]}, {"Citation": "Contreras CM, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 2008;68:759\u2013766. doi: 10.1158/0008-5472.CAN-07-5014.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-5014", "18245476"]}, {"Citation": "Amin RM, et al. LKB1 protein expression in neuroendocrine tumors of the lung. Pathol. Int. 2008;58:84\u201388. doi: 10.1111/j.1440-1827.2007.02194.x.", "ArticleIdList": ["10.1111/j.1440-1827.2007.02194.x", "18199157"]}, {"Citation": "Sahin F, et al. Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod. Pathol. 2003;16:686\u2013691. doi: 10.1097/01.MP.0000075645.97329.86.", "ArticleIdList": ["10.1097/01.MP.0000075645.97329.86", "12861065"]}, {"Citation": "Cox AD, et al. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 2014;13:828\u2013851. doi: 10.1038/nrd4389.", "ArticleIdList": ["10.1038/nrd4389", "PMC4355017", "25323927"]}, {"Citation": "Yue D, Sun X. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. Cell Death Dis. 2018;9:935\u2013945. doi: 10.1038/s41419-018-0960-8.", "ArticleIdList": ["10.1038/s41419-018-0960-8", "PMC6141589", "30224718"]}, {"Citation": "Durcan TM, et al. USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. EMBO J. 2014;33:2473\u20132491. doi: 10.15252/embj.201489729.", "ArticleIdList": ["10.15252/embj.201489729", "PMC4283406", "25216678"]}, {"Citation": "Michel MA, Swatek KN, Hospenthal MK, Komander D. Ubiquitin linkage-specific affimers reveal insights into K6-linked ubiquitin signaling. Mol. Cell. 2017;68:233\u2013246.e235. doi: 10.1016/j.molcel.2017.08.020.", "ArticleIdList": ["10.1016/j.molcel.2017.08.020", "PMC5640506", "28943312"]}, {"Citation": "Wu-Baer F, Lagrazon K, Yuan W, Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 2003;278:34743\u201334746. doi: 10.1074/jbc.C300249200.", "ArticleIdList": ["10.1074/jbc.C300249200", "12890688"]}, {"Citation": "Heidelberger JB, et al. Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. EMBO Rep. 2018;19:e44754. doi: 10.15252/embr.201744754.", "ArticleIdList": ["10.15252/embr.201744754", "PMC5891417", "29467282"]}, {"Citation": "Anderson DJ, et al. Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. Cancer Cell. 2015;28:653\u2013665. doi: 10.1016/j.ccell.2015.10.002.", "ArticleIdList": ["10.1016/j.ccell.2015.10.002", "PMC4941640", "26555175"]}, {"Citation": "Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12:94\u2013107. doi: 10.1186/s12915-014-0094-0.", "ArticleIdList": ["10.1186/s12915-014-0094-0", "PMC4226866", "25385277"]}, {"Citation": "Perez-Riverol Y, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50:D543\u2013d552. doi: 10.1093/nar/gkab1038.", "ArticleIdList": ["10.1093/nar/gkab1038", "PMC8728295", "34723319"]}]}], "History": [{"Year": "2023", "Month": "1", "Day": "5"}, {"Year": "2023", "Month": "11", "Day": "15"}, {"Year": "2023", "Month": "10", "Day": "17"}, {"Year": "2024", "Month": "1", "Day": "8", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "1", "Day": "5", "Hour": "0", "Minute": "42"}, {"Year": "2024", "Month": "1", "Day": "4", "Hour": "23", "Minute": "16"}, {"Year": "2024", "Month": "1", "Day": "5"}], "PublicationStatus": "epublish", "ArticleIdList": ["38177135", "PMC10766984", "10.1038/s41392-023-01706-y", "10.1038/s41392-023-01706-y"]}}]}